Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: RT who wrote (5922)	3/17/1998 6:49:00 AM
From: blankmind	Read Replies (2) \| Respond to of 23519

- Vivus's cash position (roughly $94 mill less $20 of a/p as of 12/31/97) shouldn't be too badly hit on 3/31/98 - even though profits will be flat due to advertising and new plant. - Concerning the impact of the "at-risk" product of the new plant on 1st 1/4 results: they won't be included as revenue. The costs won't drag down earnings either - rather - look for them to show up in "Inventory." Inventory will go from $9 mill to $13 or $14 mill. - Vivus truly needs MCA approval in the 2nd 1/4 at the latest - which I think/hope is a done deal. - My point: Lousy 1st 1/4 already reflected in stock price. Stellar 2nd & remaining quarters on the way. Despite Viagra. Regards.